Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Olema Pharmaceuticals, Inc.OLMA · Entity 613 | CHIEF SCIENTIFIC OFFICER | February 01, 2022 | February 03, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Olema Pharmaceuticals, Inc.
Report date February 01, 2022 · Filed February 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.02 · Expires 2032-01-31 | Direct | 61,750 |
Reported balance
After 2022-02-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-02-01 · Grant · Acquired 61,750 · Balance 61,750 F1: 25% of the shares subject to the option vest on February 1, 2023 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the option vest on February 1, 2023 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 01, 2022 Filed Feb 3, 2022 19:12 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (Right to Buy) · Derivative | 61,750 | $0.00 Strike: $7.02 | $0.00 |
DisclosureSEC source: 0001415889-22-001060 · form4-02032022_040213.xml · derivative · entry 1 Kushner Peter J. · CIK 0001831217 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,750 Underlying: Common Stock · 61,750 shares Expires 2032-01-31 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 1, 2023 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| November 23, 2020 Filed Nov 23, 2020 16:32 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | ConversionSeries A-1 Convertible Preferred Stock · Derivative | 130,159 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-059973 · doc4.xml · derivative · entry 4 Kushner Peter J. · CIK 0001831217 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 130,159 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock automatically converted into shares of Common Stock. F1 · price: The shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock automatically converted into shares of Common Stock. F1 · derivative.exercise_date: The shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock automatically converted into shares of Common Stock. F1 · derivative.expiration_date: The shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock automatically converted into shares of Common Stock. Read SEC document |
| November 23, 2020 Filed Nov 23, 2020 16:32 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | ConversionSeries A Convertible Preferred Stock · Derivative | 228,761 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-059973 · doc4.xml · derivative · entry 3 Kushner Peter J. · CIK 0001831217 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 228,761 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock automatically converted into shares of Common Stock. F1 · price: The shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock automatically converted into shares of Common Stock. F1 · derivative.exercise_date: The shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock automatically converted into shares of Common Stock. F1 · derivative.expiration_date: The shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock automatically converted into shares of Common Stock. Read SEC document |
| November 23, 2020 Filed Nov 23, 2020 16:32 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | ConversionCommon Stock | 130,159 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-059973 · doc4.xml · nonDerivative · entry 2 Kushner Peter J. · CIK 0001831217 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,431,672 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock automatically converted into shares of Common Stock. Read SEC document |
| November 23, 2020 Filed Nov 23, 2020 16:32 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | ConversionCommon Stock | 228,761 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-059973 · doc4.xml · nonDerivative · entry 1 Kushner Peter J. · CIK 0001831217 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,301,513 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock automatically converted into shares of Common Stock. Read SEC document |
| November 18, 2020 Filed Nov 19, 2020 18:55 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (Right to Buy) · Derivative | 179,340 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0001209191-20-059521 · doc4.xml · derivative · entry 2 Kushner Peter J. · CIK 0001831217 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,340 Underlying: Common Stock · 179,340 shares Expires 2030-11-17 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on November 18, 2021 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| June 15, 2020 Filed Nov 19, 2020 18:55 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantCommon Stock | 143,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-059521 · doc4.xml · nonDerivative · entry 1 Kushner Peter J. · CIK 0001831217 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,072,752 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.